Oxford Biomedica sees new investment for manufacturing; Twist gets a partner to help build out discovery libraries 

Oxford Biomedica has landed some new cash.

The British gene and cell therapy biotech announced Wednesday it has secured an investment “just over” £50 million from the Serum Institute of India’s investment arm. Funds are expected to help Oxford Biomedica build out its 84,000-square-foot manufacturing facility and bring online several independent suites by mid-2023.